Zacks: Brokerages Expect Agenus Inc. (AGEN) to Post -$0.36 Earnings Per Share

Brokerages expect Agenus Inc. (NASDAQ:AGEN) to announce earnings of ($0.36) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Agenus’ earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.37). Agenus reported earnings of ($0.24) per share in the same quarter last year, which would indicate a negative year over year growth rate of 50%. The business is scheduled to issue its next quarterly earnings report before the market opens on Thursday, August 3rd.

On average, analysts expect that Agenus will report full-year earnings of ($1.14) per share for the current fiscal year. For the next year, analysts anticipate that the business will report earnings of ($1.37) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that follow Agenus.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.14. Agenus had a negative net margin of 257.79% and a negative return on equity of 37,577.49%. The company had revenue of $26.96 million during the quarter, compared to analysts’ expectations of $5.22 million.

Several equities research analysts recently weighed in on AGEN shares. Maxim Group restated a “buy” rating and issued a $7.00 price target on shares of Agenus in a research report on Sunday, April 23rd. HC Wainwright set a $5.00 price target on shares of Agenus and gave the stock a “hold” rating in a research report on Saturday, May 6th. Zacks Investment Research upgraded shares of Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target on the stock in a research report on Wednesday, July 5th. ValuEngine cut shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 8th. Finally, BidaskClub upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, July 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Agenus currently has an average rating of “Buy” and a consensus target price of $5.88.

Large investors have recently made changes to their positions in the company. Chicago Equity Partners LLC boosted its stake in shares of Agenus by 42.6% in the first quarter. Chicago Equity Partners LLC now owns 454,830 shares of the biotechnology company’s stock valued at $1,715,000 after buying an additional 135,950 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Agenus by 1.9% in the first quarter. Wells Fargo & Company MN now owns 466,799 shares of the biotechnology company’s stock valued at $1,759,000 after buying an additional 8,921 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Agenus by 175.7% in the first quarter. SG Americas Securities LLC now owns 37,171 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 23,689 shares in the last quarter. State Street Corp boosted its stake in shares of Agenus by 64.3% in the fourth quarter. State Street Corp now owns 3,502,274 shares of the biotechnology company’s stock valued at $14,430,000 after buying an additional 1,370,515 shares in the last quarter. Finally, Neuberger Berman Group LLC purchased a new position in Agenus during the first quarter worth $273,000. Institutional investors own 42.61% of the company’s stock.

Shares of Agenus (NASDAQ:AGEN) traded down 0.112% during midday trading on Monday, hitting $4.475. 956,599 shares of the stock were exchanged. The firm has a 50-day moving average of $4.20 and a 200-day moving average of $3.90. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The company’s market capitalization is $443.55 million.

COPYRIGHT VIOLATION NOTICE: This piece was posted by BBNS and is owned by of BBNS. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/zacks-brokerages-expect-agenus-inc-agen-to-post-0-36-earnings-per-share-updated-updated/1314967.html.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.